MAPT and Alzheimer disease: While a lack of measure of biomarker status (amyloid and tau; see “Limitations and future directions”) prevented us from discussing the possibility of sample heterogeneity, the higher efficiency in the anterior/ventral DN in AD than bvFTD could reflect compensatory neural activity [20, 110].